HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Inclusion Criteria: * ECOG performance status of 0 or 1; * Histologically confirmed NHL or CLL with disease progression or intolerance to either ≥2 prior regimens. Patients with CLL/SLL and indolent NHL must meet criteria for systemic therapy. Patients with gastric extranodal MZL who are H. pylori positive must have failed H. pylori eradication therapy. * Availability of tumor sample: This may be an archival tissue sample obtained after most recent therapy or a fresh biopsy; if tumor sample is not available for patients in dose escalation, the Sponsor may waive the requirement after discussion. * Dose expansion stage only: Patients must have been treated with 1 prior regimen containing a BTK inhibitor in cohorts 1 to 5; * Expected survival of more than 24 weeks as determined by the Investigator. Exclusion Criteria: * Patients with primary central nervous system lymphoma. * Any of the following laboratory abnormalities: * Absolute neutrophil count (ANC) \<0.75×109/L * Hemoglobin \<8 mg/L * Platelets \<50×109/L * Note: In the dose expansion stage, patients with cell counts below the thresholds listed above may be considered eligible if there is documented bone marrow infiltration and Sponsor approval * Inadequate organ function * International normalized ratio (INR) \>1.5×ULN, activated partial thromboplastin time (aPTT) \>1.5×ULN \- Patients requiring anticoagulation therapy (except vitamin K antagonists \[ie, warfarin\]) but with a stable INR within the recommended range according to the local guideline are eligible. * Patients with presence of second primary malignant tumors within the last 2 years, with the exception of the following: * Basal cell carcinoma of the skin * Squamous cell carcinoma of the skin * Carcinoma in situ of the cervix * Carcinoma in situ of the breast * Clinically significant history of liver disease, including cirrhosis or current known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or cytomegalovirus (CMV). * Cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, vaccine, or radiotherapy within 3 weeks prior to initiation of study treatment. For oral targeted therapies, a washout period of 5 half-lives of the agent (minimum 3 days) prior to the initiation of study treatment can be used. * Any granulocyte colony-stimulating factor treatment/blood transfusion within 7 days before the screening hematology test. * Prior use of any drug that is a strong inducer or inhibitor of CYP3A4 within 2 weeks prior to initiation of study treatment. * Prior use of proton pump inhibitors (PPIs) within 5 days of study treatment * Any transplant within 100 days prior to initiation of study treatment * Clinically significant active infection or with an unexplained fever. * Treatment within a clinical study of an investigational agent or using an investigational device within 3 weeks prior to initiation of the current study treatment. * AEs from prior antineoplastic therapy that have not resolved to grade \<1 * Pregnant (positive urine or serum beta human chorionic gonadotropin test) or lactating women. * New Your Heart Association (NYHA) class II or greater congestive heart failure. NOTE: Only key inclusion/exclusion criteria are listed. Full details are in the protocol.